We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jeffrey Holzbeierlein

Jeffrey Maxwell Holzbeierlein MD

Director of the Division of Urologic Oncology, University of Kansas Hospital, Director of Clinical Research for the Urology Department at Kansas University, Kansas City, KS.

Dr. Jeffrey Maxwell Holzbeierlein, is a native of Edmond, Oklahoma.  He attended Vanderbilt University where he played on the men’s tennis team for his 4 years and was the captain of the team during his senior year.  He then completed his medical degree at the University of Oklahoma before returning to Vanderbilt to complete his residency in Urology.  After completion of his residency, Dr. Holzbeierlein spent 2 years doing his fellowship at Memorial Sloan Kettering Cancer Center in Urologic Oncology before joining the faculty at the University of Kansas Medical Center in Kansas City, Kansas in 2002. 

Dr. Holzbeierlein’s research interests focus on the androgen receptor and Heat Shock Protein 90.  He continues to have an active basic science laboratory whose work has been supported by a Department of Defense New Investigator award on which he was the Principal Investigators and 2 R01 grants on which he is a co-investigator.  His clinical research has focused on bladder cancer including identification of clinical factors that predict response to chemotherapy and immunonutrition for patients undergoing cystectomy.  He is currently, the Director of the Division of Urologic Oncology at the University of Kansas Hospital and the Director of Clinical Research for the Urology Department at KU.  He has numerous peer reviewed publications both in basic science and clinical research.